Skip to main content
OpenTrials
Completed

NCT Number: NCT00467766

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

A unique multinational study was conducted simultaneously in the USA, England and Australia. The goals of the study were to answer two questions: Does psychosocial support for the family enhance the effectiveness of drug treatment for Alzheimer's disease? Is the added value of psychosocial support the same in all 3 countries?

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Prince of Wales Hospital, Randwick, New South Wales, Australia

Loading trial locations.

About this study

This study is a single-blind prospective randomized trial with 150 patient/caregiver pairs (50 in each country). Eligibility criteria at baseline require that the primary caregiver is the spouse of the patient; the patient must have a diagnosis of AD, be in the in mild to moderate stage of dementia, be living with the caregiver, and be willing to take Donepezil (Aricept). These participants were randomly assigned to one of two groups: in one group, the intervention consists of drug treatment for the patient plus psychosocial intervention for the caregiver; in the other group the intervention consists solely of drug treatment for the patient.

The intervention for the caregiver consists of 5 scheduled individual and family counseling sessions within 3 months of baseline, and unlimited consultations on request. Assessments were conducted every 3 months for the first year and every 6 months for a second year. There are 3 sources of data: an interview of the caregiver by an independent rater, an assessment of the patient, and a count of the amount of medication used. Thus we will be able to assess the effect of adding counseling to medication for the caregiver, for the patient, and on compliance with medication use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals diagnosed with mild to moderate stage Alzheimer's disease and their spouse caregivers

Exclusion criteria

  • Severe psychological or physical illness
  • Unwillingness by either spouse to participate in all aspects of the study

Treatment and study plan

Psychosocial information, counseling, and support

Behavioral

Donepezil (Aricept)

Drug

Primary outcomes

  1. Caregiver: Changes in depression, measured with the Beck Depression Inventory

    Time frame: every 3 months for the first year, and every 6 months for the second year

  2. Caregiver: Changes in social support satisfaction, measured with the Stokes Social Network Scale

    Time frame: every 3 months for the first year, and every 6 months for the second year

  3. Patient: Changes in cognition measured by ADAS-cog

    Time frame: every 3 months for the first year, and every 6 months for the second year

  4. Patient: Changes in abilities with activities of daily living measured by ADCS-ADL

    Time frame: every 3 months for the first year, and every 6 months for the second year

Secondary outcomes

  1. Caregiver: Changes in reactions to patient behavior, physical health, family conflict and sense of mastery

    Time frame: every 3 months for the first year, and every 6 months for the second year

  2. Patient: Time to nursing home placement

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Important dates

Study start
1999
Study completion
2003
First posted
May 1, 2007
Registry last updated
May 7, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.